ReviewJournal of the Korean Society of Radiology2025
조영증강 유방촬영술: 현재의 임상적 활용과 미래 방향에 대한 종합적 고찰.
Review in Journal of the Korean Society of Radiology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Contrast-enhanced mammography (CEM) is an advanced imaging technique that combines morphological and functional information to enhance breast cancer detection, similar to MRI. Using dual-energy X-rays and iodinated contrast agents, CEM highlights enhancing abnormalities and is highly sensitive in detecting malignancies, particularly in dense breasts. Its advantages include rapid image acquisition and cost-effectiveness, making it useful in screening, diagnosis, staging, and monitoring of chemotherapy response. Emerging applications of radiomics and artificial intelligence are poised to improve lesion characterization and predict molecular subtypes. While promising, CEM also has limitations, including increased radiation exposure, risks associated with contrast, potential for false results, and difficulty in widespread integration because of the limited availability of CEM-guided biopsy. Overall, CEM is a valuable and cost-effective tool with increased clinical relevance. This review provides a comprehensive summary of CEM for clinical and future considerations.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.